Venture Capital Perspective: Carlo Rizzuto, Versant Ventures
Join us for a discussion and Q&A with Carlo Rizzuto, operating principal of Versant Ventures, a leading healthcare investment firm investing across the sector at all stages, with an emphasis on early-stage investment in therapeutics. Carlo will discuss Versant Ventures’ new $300 million fund for investing in bioscience, as well as other recent exciting developments and trends in venture capital and healthcare investing.
About the speaker:
Carlo Rizzuto is an Operating Principal with Versant Ventures and focuses on biotech investing and company building. Currently based in Versant’s European office, Carlo will soon return to his local roots to open a Versant office in New York City.
Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising US and European clients in the pharmaceutical, payor and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup.
Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.